A Dietary Supplement in Treatment of Glaucoma
About the Research Project
Program
Award Type
Standard
Award Amount
$180,000
Active Dates
September 01, 2020 - August 31, 2024
Grant ID
G2020286
Co-Principal Investigator(s)
Ying Li, MD, PhD, Emory University
Goals
Mitochondria are the energy factories of cells. The mitochondria of RGCs lose function with age, probably due to age-related loss of nicotinamide adenine dinucleotide (NAD+), an enzyme cofactor needed for energy production, making the cells more susceptible to damage. The goal of this study is to test whether systemic delivery of the NAD+ precursor nicotinamide riboside, a dietary supplement, increases retinal NAD+ and protects RGCs in glaucoma models.
Summary
The mitochondria of retinal ganglion cells lose function with age, probably due to age-related loss of nicotinamide adenine dinucleotide (NAD+), an enzyme cofactor needed for energy production. The cells thus become more susceptible to damage from, for instance, elevated pressure in the eye, a common risk factor for glaucoma. We propose to test whether systemic delivery of the NAD+ precursor nicotinamide riboside, a dietary supplement, increases retinal NAD+ and protects retinal ganglion cells in mouse models of glaucoma.
Related Grants
National Glaucoma Research
The Immune Landscape of the Human Optic Nerve Head
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Monica Vetter, PhD
Current Organization
University of Utah
The Immune Landscape of the Human Optic Nerve Head
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Monica Vetter, PhD
Current Organization
University of Utah
National Glaucoma Research
Understanding Optic Nerve Head Astrocyte Contributions to Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Evan Cameron, PhD
Current Organization
Cleveland Clinic - Lerner Research Institute
Understanding Optic Nerve Head Astrocyte Contributions to Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Evan Cameron, PhD
Current Organization
Cleveland Clinic - Lerner Research Institute
National Glaucoma Research
Exploring Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Qi Cui, MD, PhD
Current Organization
University of Pennsylvania, Perelman School of Medicine
Exploring Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Qi Cui, MD, PhD
Current Organization
University of Pennsylvania, Perelman School of Medicine